Reiter, Andreas http://orcid.org/0000-0002-7718-6507
Gotlib, Jason
Álvarez-Twose, Iván
Radia, Deepti H.
Lübke, Johannes http://orcid.org/0000-0003-0767-1504
Bobbili, Priyanka J.
Wang, Aolin
Norregaard, Chelsea
Dimitrijevic, Saša
Sullivan, Erin
Louie-Gao, Melinda
Schwaab, Juliana
Galinsky, Ilene A.
Perkins, Cecelia
Sperr, Wolfgang R.
Sriskandarajah, Priya
Chin, Andi
Sendhil, Selvam R.
Duh, Mei Sheng
Valent, Peter http://orcid.org/0000-0003-0456-5095
DeAngelo, Daniel J. http://orcid.org/0000-0001-7865-2306
Funding for this research was provided by:
Blueprint Medicines Corporation
Article History
Received: 16 March 2022
Revised: 5 May 2022
Accepted: 25 May 2022
First Online: 5 July 2022
Competing interests
: AR, JG, IÁ-T, DHR, JL, JS, IAG, CP, WRS, PS, PV, and DJD are affiliated with institutions that have received consulting fees for this study from Blueprint Medicines Corporation. CN, SD, ES, and ML-G are employees of Blueprint Medicines Corporation and hold stock/options. PJB, AW, AC, SRS, and MSD are employees of Analysis Group, Inc., which has received consulting fees from Blueprint Medicines Corporation for the conduct of this research. AR was a member of the Study Steering Committee for the global trial of midostaurin (Novartis), the RAC for studies of avapritinib in AdvSM (Blueprint Medicines Corporation), and the Study Steering Committee for the phase II trial of ripretinib in AdvSM (Deciphera Pharmaceuticals); has received research funding for the conduct of these trials; and has received honoraria and reimbursement of travel expenses from Novartis, Blueprint Medicines Corporation, and Deciphera Pharmaceuticals. JG has received consulting fees and research funding from Blueprint Medicines Corporation, Deciphera, Incyte and Kartos Therapeutics, and has served as chair of the RAC for Blueprint Medicines Corporation’ EXPLORER study, and for the PATHFINDER study, and as co-chair for the Deciphera Study Steering Committee for ripretinib in AdvSM, and chair of the Central Response Review Committee for the phase 2 study of bezuclastinib in AdvSM. IÁ-T is the principal investigator of the PATHFINDER study in Spain and has received advisory board fees from Blueprint Medicines Corporation; and has participated in educational events for Novartis. DHR has received consulting fees and research funding from Blueprint Medicines Corporation, is a member of the RACs for the EXPLORER and PATHFINDER studies, and has received honoraria from Novartis for educational events and consultancy. JS has received advisory board fees from Blueprint Medicines Corporation and Novartis. PV has received honoraria from AOP Orphan Pharmaceuticals, Blueprint Medicines Corporation, Celgene, Novartis, and Pfizer. DJD has served as a consultant for Amgen, Agios, Autolus, Blueprint Medicines Corporation, Forty-Seven, Incyte Corporation, Jazz, Novartis, Pfizer, Shire and Takeda, and received research funding from AbbVie, Blueprint Medicines Corporation, GlycoMimetics and Novartis. JL, IAG, CP, WRS, and PS have no further competing interests to report.